
TRPXD
Healthcare · Biotechnology · $24.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2018
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 27, 2019 | Time not confirmed | — | -69.84 | — |
| Dec 3, 2018 | Time not confirmed | — | -34.78 | — |
| Aug 20, 2018 | Time not confirmed | -0.59 | -0.35 | +40.7% |
| Jun 1, 2018 | Time not confirmed | -0.55 | -0.59 | -7.3% |
| Feb 28, 2018 | Time not confirmed | -0.51 | -0.41 | +19.6% |
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the…